Physician profile
John M Jacobs
NPI 1881785046
$1,590.87
in general payments reported to CMS, 2019-2025
27 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $92.68 · 2023: $300 · 2024: $558 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.99 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $275.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $259.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $134.43 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.25 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $99.15 | 2019-2025 | |
| Novo Nordisk INC | $90.53 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $65.62 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Insulet Corporation | $57.97 | 2023-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $51.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $47.74 | 2024 | Injectafer |
| Ethicon INC. | $41.85 | 2025 | Monarch Platform |
| Intuitive Surgical, INC. | $39.92 | 2019 | |
| Lilly USA, LLC | $31.45 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $31.40 | 2019 | |
| Dexcom, INC. | $31.21 | 2023 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.41 | 2023 | Watchman Access System |
| Neurocrine Biosciences, INC. | $23.03 | 2024 | Ingrezza |
| Collegium Pharmaceutical, INC. | $21.92 | 2025 | Jornay Pm |
| Alnylam Pharmaceuticals INC. | $21.43 | 2025 | Givlaari |
| Abbott Laboratories | $19.79 | 2024 | Freestyle Libre 3 |
| Seqirus USA INC | $19.45 | 2019 | |
| Amarin Pharma, INC. | $15.07 | 2020 | |
| Amgen INC. | $14.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.60 | 2023 | Qelbree |
| Depuy Synthes Sales INC. | $13.32 | 2023 | Monovisc, Orthovisc |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2019 | |
| Sanofi Pasteur INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.